During MF progression, CXCR4 and CXCL12 expressions increase concomitantly as the disease advances from the plaque to the tumor stage, reinforcing the crucial involvement of this signaling axes in CTCL development and progression [72]. The gene discussed is CXCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.